Diana Whitaker‐Menezes

Thomas Jefferson University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

53h-index11.4kcitations143works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(59), Metabolism, Diabetes, and Cancer(24), Caveolin-1 and cellular processes(24), Cell Adhesion Molecules Research(23), Autophagy in Disease and Therapy(15)

Publications143 total

Supplementary Figure S8 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
2025Open Access
Supplementary Figure S2 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
2025Open Access
Supplementary Figure S3 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
2025Open Access
Supplementary Figure S7 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
2025Open Access
Supplementary Figure S11 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
2025Open Access
Supplementary Figure S10 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
2025Open Access
Supplementary Figure S9 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
2025Open Access
Data from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
2025Open Access
Supplementary Figure S4 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
2025Open Access
Supplementary Figure S6 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
2025Open Access
Supplementary Figure S1 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
2025Open Access
Supplementary Figure S5 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
2025Open Access
Supplementary Tables S1-S10 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
2025Open Access
15 Augmenting immune checkpoint inhibitor therapy in a head and neck squamous cell carcinoma mouse model using ultrasound-triggered microbubble cavitation
Regular and Young Investigator Award Abstracts·2025Open Access
Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
Clinical Cancer Research·2025· 1 citedOpen Access
<scp>TOMM20</scp> as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis
Molecular Oncology·2025· 1 citedOpen Access
Author response for "&lt;scp&gt;TOMM20&lt;/scp&gt; as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis"
2024
Author response for "&lt;scp&gt;TOMM20&lt;/scp&gt; as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis"
2024
MiR-200c reprograms fibroblasts to recapitulate the phenotype of CAFs in breast cancer progression
Cell Stress·2024· 5 citedOpen Access
TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c‐MYC and NFkB activation in breast cancer
International Journal of Cancer·2023· 24 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Michael P. Lisanti(42), Federica Sotgia(41), Ubaldo Martinez‐Outschoorn(38), Anthony Howell(33), Richard G. Pestell(32), Stephanos Pavlides(19), Barbara Chiavarina(14), Neal Flomenberg(13), Agnieszka K. Witkiewicz(13), Renee M. Balliet(10), Lin Zhao(10), Aristotelis Tsirigos(9), Ruth Birbe(9), Zhao Lin(8), Mathew C. Casimiro(6), Gloria Bonuccelli(6), Claudia Capparelli(6), Sharon Sneddon(6), G Migneco(6), Philippe G. Frank(5)